Keith Meister Sells 214,596 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 214,596 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $163.51, for a total transaction of $35,088,591.96. Following the completion of the sale, the director owned 3,065,452 shares of the company’s stock, valued at approximately $501,232,056.52. This represents a 6.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Illumina Price Performance

NASDAQ ILMN opened at $162.55 on Wednesday. The company has a market cap of $24.59 billion, a PE ratio of 29.55, a P/E/G ratio of 2.72 and a beta of 1.50. The firm’s 50 day moving average price is $134.48 and its 200-day moving average price is $132.39. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a 52-week low of $78.79 and a 52-week high of $165.97.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, signaling confidence in further upside for the genomics leader. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are being optimized on Illumina software, a small but constructive development that could reinforce Illumina’s ecosystem in cancer research and data analysis. Business Wire article
• Neutral Sentiment: Recent news about genomics and synthetic biology stocks being in the spotlight highlights ongoing investor interest in the sector, though the coverage did not specifically point to Illumina as a named leader in those articles. Yahoo Finance article
• Neutral Sentiment: Illumina reported strong prior-quarter results, beating EPS and revenue estimates and maintaining FY2026 guidance, which continues to underpin the stock’s fundamental case. MarketBeat article
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, and CAO Scott D. Ericksen also sold stock. While the sales were disclosed and one was under a 10b5-1 plan, the size and frequency of insider selling can weigh on investor sentiment. SEC filing

Institutional Investors Weigh In On Illumina

Institutional investors have recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after acquiring an additional 79 shares in the last quarter. HighPoint Advisor Group LLC boosted its stake in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares in the last quarter. Meeder Advisory Services Inc. boosted its stake in Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares in the last quarter. Toronto Dominion Bank grew its position in Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares during the last quarter. Finally, Assetmark Inc. increased its stake in Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ILMN. Citigroup increased their price target on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Canaccord Genuity Group cut their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Weiss Ratings lowered shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Barclays increased their target price on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Finally, UBS Group restated a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $138.38.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.